Cutiss Company
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
Industry:
Medical Technology
Headquarters:
Zurich
Founded Date:
08.03.2017
Employees Number:
11—50
Estimated Revenue:
$1-10 Mn
Register and Claim Ownership